Date: 2013-12-17
Type of information: Production agreement
Compound: OS2966 monoclonal antibody program
Company: CMC Biologics (Denmark - USA) Oncosynergy (USA-France)
Therapeutic area: Cancer - Oncology
Type agreement: development
manufacturing
production
Action mechanism:
Disease:
Details: * On December 17, 2013, CMC Biologics and OncoSynergy have announced that they have entered into an agreement for cell-line development, process development, analytical development and manufacturing of non-GMP material to enable early toxicology testing and cGMP material for IND enabling toxicology studies and Phase I clinical trials. This work will advance OncoSynergy’s OS2966 monoclonal antibody program based on its “Targeted Synergy” approach – a transformative strategy allowing broad inhibition of multiple fundamental cancer growth mechanisms with a single drug. The project will be executed by CMC Biologics at its Copenhagen development and manufacturing facility. OncoSynergy EU SAS in France will lead the project.
Financial terms:
Latest news:
